EGFR
Fast, accurate treatment decisions for NSCLC patients
ASPYRE’s comprehensive lung panel simultaneously analyzes DNA and RNA from blood or tissue in a single assay, enabling straightforward, precise identification of all NCCN guideline recommended genomic biomarkers associated with approved targeted therapies for NSCLC.
Fast time to treatment
ASPYRE-Lung dramatically simplifies and accelerates the detection of actionable biomarkers, enabling you to identify targeted treatment options within days of diagnosis.
Reduced sample requirement
ASPYRE’s high sensitivity enables testing from tissue samples with as little as 10% tumor content, compared to 20% or 30% for most competing assays.
Actionable results
ASPYRE accelerates and simplifies analysis by eliminating the noise from genomic data, ensuring accuracy for the markers that are of interest, to enable more confident decision-making.
Ultra-sensitive
ASPYRE’s high sensitivity enables accurate biomarker analysis from blood or tissue, even from limited samples with low tumor content.
Biomarkers included in ASPYRE-Lung
ASPYRE-Lung enables the simultaneous analysis of 77 DNA mutations & 37 RNA fusions.
DNA
Exon 18
- G719A
- G719S
- G719C
Exon 19
- Deletions
- Insertions
Exon 20
- T790M
- S7681
- C797S
- Insertions
Exon 21
- L858R
- L861Q
BRAF
Exon 15
- V600E
KRAS
Exon 2
- G12A
- G12C
- G12D
- G12F
- G12R
- G12S
- G12V
Exon 2
- G13A
- G13C
- G13D
- G13R
- G13S
Exon 3
- Q61E
- Q61H
- Q61K
- Q61L
- Q61R
ERBB2
Exon 17
- V659E
Exon 20
- Insertions
RNA
ALK
RET
MET
NTRK1
NTRK2
NTRK3
ROS1
Featured resources & publications


